Relevance of Blast Counts for Genetic Subclassification in MDS
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G
. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024; 11(11):e862-e872.
DOI: 10.1016/S2352-3026(24)00251-5.
View
2.
Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J
. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719.
PMC: 9252913.
DOI: 10.1038/s41375-022-01613-1.
View
3.
Huber S, Haferlach T, Muller H, Meggendorfer M, Hutter S, Hoermann G
. MDS subclassification-do we still have to count blasts?. Leukemia. 2023; 37(4):942-945.
PMC: 10079547.
DOI: 10.1038/s41375-023-01855-7.
View
4.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H
. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood. 2024; 144(15):1617-1632.
PMC: 11487646.
DOI: 10.1182/blood.2023023727.
View
5.
Chen X, Fromm J, Naresh K
. "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?. Leukemia. 2022; 36(2):327-332.
DOI: 10.1038/s41375-021-01498-6.
View